Final Approval Hearing Set For $73M Settlement For EpiPen Antitrust Claims
KANSAS CITY, Kan. — A final approval hearing for a $73 million settlement reached with Mylan NV, Mylan Specialty LP and Mylan Pharmaceuticals Inc. (collectively, Mylan) to end claims that they...To view the full article, register now.
Already a subscriber? Click here to view full article